MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced on Sept. 26, 2023 that it has opened two new good manufacturing practice (GMP)-grade messenger RNA (mRNA) drug substance manufacturing sites in Darmstadt and Hamburg, Germany. The company has invested €28 million (US$30 million) into the new Darmstadt and Hamburg GMP mRNA drug substance manufacturing sites. Source: Biopharm International 28/9/2023